Wada H, Mori Y, Kaneko T, Wakita Y, Minamikawa K, Ohiwa M, Tamaki S, Yokoyama N, Kobayashi T, Deguchi K
Mie University School of Medicine, Japan.
Clin Ther. 1992 Nov-Dec;14(6):829-34.
Molecular markers of the coagulation system and the effects of pravastatin on lipid levels and the coagulation markers were studied in 48 patients (mean age, 55 years) with hypercholesterolemia (plasma total cholesterol levels > 280 mg/dl). Each patient received 10 mg of pravastatin daily for 3 months. Plasma total cholesterol and low-density lipoprotein cholesterol levels decreased significantly during treatment and high-density lipoprotein cholesterol levels increased significantly. Above-normal plasma levels of thrombin-antithrombin III complex, fibrinopeptide A, FDP-D-dimer, plasminogen activator inhibitor-I, and thrombomodulin were found in the patients before treatment; each of these was reduced significantly during treatment. The findings suggest the presence of a hypercoagulable state in hypercholesterolemia and that pravastatin might prevent the hypercoagulable state by reducing hypercholesterolemia.
对48例（平均年龄55岁）高胆固醇血症（血浆总胆固醇水平>280mg/dl）患者的凝血系统分子标志物以及普伐他汀对血脂水平和凝血标志物的影响进行了研究。每位患者每天服用10mg普伐他汀，持续3个月。治疗期间血浆总胆固醇和低密度脂蛋白胆固醇水平显著降低，高密度脂蛋白胆固醇水平显著升高。治疗前患者血浆中凝血酶 - 抗凝血酶III复合物、纤维蛋白肽A、FDP - D - 二聚体、纤溶酶原激活物抑制剂 - I和血栓调节蛋白水平高于正常；治疗期间这些指标均显著降低。这些发现提示高胆固醇血症中存在高凝状态，且普伐他汀可能通过降低高胆固醇血症来预防高凝状态。
